Atugen Raises €5 Million in Third Round of Finaning
Atugen, which recently entered the RNAi therapeutics field, said this week that it has raised €5 million (about $6.1 million) in its third round of financing.
The company said that the financing round was managed by WestLBPanmure, and was co-led by Novartis Venture Fund and funds advised by Apax Partners. Also joining in the financing was current Atugen investor MPM Capital.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
